Funding momentum Acurex has recently secured over 18M in seed funding and continues to attract grants from prestigious institutions and foundations, signaling strong investor confidence and a potential for strategic partnerships or co-development deals.

Clinical progression Lead program has entered IND-enabling studies with a second program in lead development, indicating near-term clinical milestones and opportunities to engage on translational biomarkers, regulatory strategy, and potential collaboration or licensing discussions.

Parkinson focus Platform targets biomarker-driven modulation in Parkinson's disease with blood-brain barrier permeable small molecules, presenting sales angles in neuroscience research collaborations, contract development, and tool or assay partnerships for neurology centers.

Academic alliances Strong backing from Stanford, UC, Michael J. Fox Foundation, Parkinson’s UK, and NIH provides a fertile network for co-development, grant-aligned projects, and access to patient cohorts and data-sharing opportunities.

Growth potential Small team (11-50 employees) with a high-innovation platform and clear near-term milestones suggests scalable collaboration models, including sponsored research, consulting, or early-access programs for pharma and biotech partners seeking neurodegeneration expertise.